Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

The SEC has fined Cassava Sciences $40 million for misleading investors on the company's Alzheimer's drug candidate simufilam ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...